Anti-CD3 Prophylaxis for Delaying Type 1 Diabetes Onset
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interventions fail to prevent or delay the onset of clinical type 1 diabetes in high-risk individuals before the clinical diagnosis, despite the potential of anti-CD3 monoclonal antibodies like teplizumab in recent-onset cases.
Innovation Solution
Administer a prophylactically effective amount of anti-CD3 antibody, such as teplizumab, to non-diabetic subjects who are HLA-DR4+ and not HLA-DR3+, and are free of antibodies against zinc transporter 8 (ZnT8), potentially combined with other agents, and monitor responsiveness through TIGIT+KLRG1+CD8+ T-cell frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If anti-CD3 monoclonal antibodies like teplizumab are administered to high-risk individuals before clinical diagnosis, then the onset of type 1 diabetes is delayed, but current interventions fail to prevent progression in Stage 1 or 2 subjects
Solution Approach 1:
The patent applies preliminary action by administering anti-CD3 monoclonal antibodies to subjects in Stage 1 or Stage 2 (pre-clinical stages) before the onset of overt hyperglycemia and clinical diabetes. This early intervention modifies the function of CD8+ T lymphocytes before they can cause significant beta cell destruction, thereby delaying progression to clinical TID. The treatment is given prophylactically to high-risk individuals who have autoantibodies but have not yet developed clinical symptoms.
2Adaptability or versatility
If anti-CD3 antibody treatment is administered to all high-risk subjects, then more individuals may benefit, but treatment responsiveness varies significantly by HLA genotype and autoantibody profile
Solution Approach 1:
The patent applies local quality by identifying specific subgroups of high-risk subjects who are most likely to respond to anti-CD3 antibody treatment. Rather than treating all high-risk individuals uniformly, the invention targets subjects with specific characteristics: HLA-DR4 positive, HLA-DR3 negative, and positive for certain autoantibodies (IAA, ICA, GAD, IA-2) but negative for ZnT8 antibodies. This selective approach increases the precision of predicting treatment response while maintaining broad applicability to the relevant subgroup.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly delays the onset of type 1 diabetes by at least 50% to 90% or up to 60 months, as demonstrated by clinical trials, indicating a substantial reduction in the progression to clinical diabetes.
Implementation Method 1
The drug modifies the function of CD8+ T lymphocytes, which are thought to be important effector cells that cause beta cell killing
Data Source
AI summary
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (TID), comprising: providing a non-diabetic subject who is at risk for TID; determining that the non-diabetic subject (1) is substantially free of antibodies against zinc transporter 8 (ZnT8), (2) is HLA-DR4+, and/or (3) is not HLA-DR3+; and administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject.